FDA approves DUCORD product for stem cell transplants

October 9, 2012

Duke University School of Medicine has received approval from the Food and Drug Administration to market DUCORD, a stem cell product derived from umbilical cord blood, for use in transplants between unrelated donors and recipients.

DUCORD is approved for use in hematopoietic for patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.

The approval marks a significant achievement for Duke and the Carolinas Cord Blood Bank (CCBB), a not-for-profit, public cord blood bank at the medical school, which has pioneered for children and adults with cancer, blood disorders and inherited diseases. Only two other cord blood banks in the United States have received FDA approval to market similar stem cell products.

"This approval and the quality it reinforces are lynchpins in Duke Medicine's commitment to developing and translating innovative cellular therapies," said Victor J. Dzau, M.D., chancellor for health affairs at Duke University and president and CEO of Duke University Health System.

"This is a major milestone in the history of the university and a significant step forward in the field of regenerative medicine at Duke and elsewhere," said Nancy Andrews, M.D., dean of the Duke University School of Medicine

, derived from cord blood and produced in the bone marrow, are able to renew themselves and differentiate into specialized cells. When transplanted in people with lymphoma, leukemia, immune disorders and genetic conditions, these robust cells can establish a life-saving new blood and immune system.

Blood from babies' umbilical cords, which was once discarded, is rich in hematopoietic stem cells. Joanne Kurtzberg, M.D., director of Duke's and Marrow Transplant Program, was a trailblazer in their use for transplants and was a founder of the public bank through CCBB. Kurtzberg has remained at the forefront of expanding the use of cord blood for patients with life-threatening diseases.

"The licensure of DUCORD is a reflection of the dedication and hard work of the entire CCBB staff over the past decade," said Kurtzberg, medical director and founder of the CCBB. "Licensure enables the CCBB to continue to provide cord blood units to patients in need of a donor for unrelated transplantation. We feel that going through the licensure process has strengthened and improved our operations. In addition, it will allow the CCBB to provide the highest quality cord blood units as source material for new clinical applications in cellular therapies in the future."

To receive the FDA license, the CCBB submitted an application documenting the steps, policies and procedures required for manufacturing high quality cord blood units, including collection, processing, testing, storing and distributing the cells.

"FDA approval is a major statement about the quality of the product and the methods used to produce it," said Robert Califf, M.D., Duke's vice chancellor for clinical research.

Prior to receiving the FDA license, CCBB provided more than 1,500 high quality cord blood units throughout the world under an FDA Investigative New Drug application. Currently, all CCBB units are listed on the National Bone Marrow and Donor Program's "Be the Match" registry, a central database for transplant centers to search and request cord blood units for patients in need of unrelated donors for transplantation.

The CCBB is also a member of the National Cord Blood Inventory of the C.W. Bill Young Cell Transplantation Program, administered through the U.S. Department of Health and Human Services.

Kurtzberg said the CCBB staff is committed to advancing the benefits of stem cells isolated from umbilical cord blood, and to improve the lives of those inflicted with inherited and acquired serious and life-threatening medical conditions.  

"Dr. Kurtzberg's program has successfully balanced the urgent pressure to innovate and find new cures for our patients with the painstaking care that prioritizes patient safety and permits rigorous regulatory review," Dzau said.

Explore further: Researchers say therapy improves stem cell engraftment in umbilical cord blood transplant recipients

Related Stories

Researchers say therapy improves stem cell engraftment in umbilical cord blood transplant recipients

December 12, 2011
A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases, a phase I clinical trial led by ...

Enhanced cord blood stem cell transplants safe in long-term studies

April 18, 2011
(Medical Xpress) -- An innovative experimental treatment for boosting the effectiveness of stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, report scientists from ...

Recommended for you

Thousands of new microbial communities identified in human body

September 20, 2017
A new study of the human microbiome—the trillions of microbial organisms that live on and within our bodies—has analyzed thousands of new measurements of microbial communities from the gut, skin, mouth, and vaginal microbiome, ...

Study finds immune system is critical to regeneration

September 20, 2017
The answer to regenerative medicine's most compelling question—why some organisms can regenerate major body parts such as hearts and limbs while others, such as humans, cannot—may lie with the body's innate immune system, ...

Immune cells produce wound healing factor, could lead to new IBD treatment

September 20, 2017
Specific immune cells have the ability to produce a healing factor that can promote wound repair in the intestine, a finding that could lead to new, potential therapeutic treatments for inflammatory bowel disease (IBD), according ...

As men's weight rises, sperm health may fall

September 20, 2017
(HealthDay)—A widening waistline may make for shrinking numbers of sperm, new research suggests.

New model may help science overcome the brain's fortress-like barrier

September 19, 2017
Scientists have helped provide a way to better understand how to enable drugs to enter the brain and how cancer cells make it past the blood brain barrier.

Cell-based therapy success could be boosted by new antioxidant

September 19, 2017
Cell therapies being developed to treat a range of conditions could be improved by a chemical compound that aids their survival, research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.